Log in
Enquire now
‌

US Patent 6924264 Modified exendins and exendin agonists

Patent 6924264 was granted and assigned to Amylin Pharmaceuticals on August, 2005 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
0
Current Assignee
Amylin Pharmaceuticals
Amylin Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
69242640
Patent Inventor Names
Andrew A. Young0
Kathryn S. Prickett0
Date of Patent
August 2, 2005
0
Patent Application Number
095612260
Date Filed
April 28, 2000
0
Patent Citations Received
‌
US Patent 11840559 Glucagon-receptor selective polypeptides and methods of use thereof
0
0
‌
US Patent 11884713 Acylated glucagon analogues
0
Patent Primary Examiner
‌
Karen Cochrane Carlson
0
Patent abstract

Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analogs, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 6924264 Modified exendins and exendin agonists

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.